The TarGeT studies investigate novel treatments for High Grade Glioma (HGG) based on the genetic characteristics of the tumour. The TarGeT-SCR study is the screening protocol where participants receive molecular profiling. This helps doctors identify which specific treatment arm of the study is best for that patient based on their genetic mutations. The study also explores new tests to track how the disease responds to treatment or why it might return. This personalised approach ensures that children and young adults receive the treatment most likely to fight their specific type of cancer.